Presentation <br />On<br />NOVARTIS<br />(A PHARMACEUTICAL<br />COMPANY)<br />SHIVANI KAKRIA<br />
SLOGAN OF  NOVARTIS<br />CARING AND CURING<br />
MISSION<br />INNOVATION IS THE ESSENCE MISSION OF NOVARTIS.<br />
VISSION<br /><ul><li>HEALTHCARE THAT FOCUSES ON CREATING,DEVELOPING AND MANUFACTURING  A WIDE RANGEOFCOMPETITIVELY DIFFERE...
HUMAN RESOURCE <br />BUILDING OF NOVARTIS<br />IN BASEL.<br />
KEY PEOPLE<br />CHAIRMAN : DANIEL VASELLA<br />CEO: JOSEPH JIMENEZ<br />
<ul><li>REVENUE:US $44.27BILLION
NETINCOME:US$8.40BILLION
OPERATING INCOME:US $9.98
EMPLOYEES:99,830
SUBSIDIARIES:CIBAVISION,SANDOZ</li></li></ul><li>NOVARTIS WINS TWO<br /> SCRIP AWARDS  FOR <br />BEST OVERALL PIPELINE<br ...
SHARE ANALYSIS OF NOVARTIS<br />
GROWTH IN VARIOUS PRODUCT CATEGORIES…..<br />
EMERGING MARKETS<br />OF NOVARTIS<br /><ul><li>CHINA
RUSSIA
TURKEY
SOUTH KOREA
BRAZIL
INDIA</li></li></ul><li>
EMERGING MARKKETS IN PHARMACEUTICALS..<br />
SOME IMP. FACTS<br /><ul><li>WE OFFER A BROAD RANGE OF HEALTHCARE  SOLUTIONS THAT MEETS</li></ul>THE EVOLVING AND UNMET NE...
ABOUT COMPANY<br /><ul><li>A PHARMACEUTICAL COMPANY
FOUNDED IN 1996,
HD.QT’S-BASEL AND SWITZERLAND.
RANKING 3 IN SALES AMONG</li></ul> WORLDWIDE INDUSTRY.<br /><ul><li>IS 6TH LARGEST IN TERMS OF REVENUE..
IS MEMBER OF EUROPEAN FEDERATION OF</li></ul>PHARMACEUTICAL INDUSTRIES ANDASSOCIATION.<br />
NOVERTIS PRODUCTS<br />
USD FIXED INCOME SECURITIES<br />
FINANCIAL DEVELOPMENTS IN<br />2009<br />NET  SALES:RISE 7%(+11% IN LOCAL CURRENCY TO USD 44.3BILLION.<br />PHARMACEUTICAL...
SOME OTHER FINANCIAL<br />DEVELOPMENTS<br />OPERATING INCOME:ADVANCES 11% TO USD 10.0 BILLION ON THE SOLID BUSINESS EXPANS...
WHAT TYPE OF BUSINESS WE ARE IN??<br /><ul><li>PHARMACEUTICAL
VACCINES AND DIAGNOSTICS
SANDOZ(GENERICS)
OVER THE COUNTER
ANIMAL HEALTH
CIBA VISION</li></li></ul><li>Comtan- $420 M (2007)- Parkinson's disease<br />Diovan- $5.0 B sales[25] (2007)- Hypertensio...
HEALTHCARE OTC<br />Benefiber<br />Buckley's cold and cough formula<br />Bufferin<br />Comtrex cold and cough<br />Denavir...
ANIMAL CARE<br /><ul><li>PETS CARE</li></ul>Interceptor (Milbemycin oxime), oral worm control product<br />Sentinel Flavor...
NET SALES BY REGION IN %<br />
CORE OPERATING INCOME <br />BY DIVISION IN %<br />
NET SALES BY DIVISION IN %<br />
COMPETITORS IN INDIA<br />NAME OF THE COUNTRY<br />DR.REDDY’S LAB<br />CIPLA<br />PIRAMAL HEALTHCARE<br />GLAXO INDIA LTD....
COMPETITORS IN SWITZERLAND<br />TOTAL REVENUE<br />    (IN USD BILLIONS)<br />47.35<br />4.26<br />NAME OF THE COUNTRY<br ...
COMPETITORS IN GERMANY<br />NAME OF THE COUNTRY<br />BAYER<br />BOEHRINGER INGELHEIM<br />MERCK kGaA<br />TOTAL REVENUE<br...
COMPETITORS IN JAPAN<br />NAME OF THE COUNTRY<br />TAKEDAPHARMACEUTICAL.<br />ASTELLAS PHARMA<br />DAIICHI  SANKYO        ...
COMPETITORS IN USA<br />TOTAL REVENUE(IN USD BILLIONS )<br />61.90<br />30.76                                             ...
COMPETITORS IN UK<br />NAMEOF THE COMPANY<br />TOTAL REVENUE<br />     (IN USD BILLIONS)<br />45.83<br />      32.81<br />...
Upcoming SlideShare
Loading in …5
×

M100700053 shivani kakria

2,416 views

Published on

marketing assignment on" NOVARTIS"

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
2,416
On SlideShare
0
From Embeds
0
Number of Embeds
8
Actions
Shares
0
Downloads
20
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

M100700053 shivani kakria

  1. 1. Presentation <br />On<br />NOVARTIS<br />(A PHARMACEUTICAL<br />COMPANY)<br />SHIVANI KAKRIA<br />
  2. 2.
  3. 3.
  4. 4. SLOGAN OF NOVARTIS<br />CARING AND CURING<br />
  5. 5. MISSION<br />INNOVATION IS THE ESSENCE MISSION OF NOVARTIS.<br />
  6. 6. VISSION<br /><ul><li>HEALTHCARE THAT FOCUSES ON CREATING,DEVELOPING AND MANUFACTURING A WIDE RANGEOFCOMPETITIVELY DIFFERENTIATED PRODUCTSTHAT RESTORE,MAINTAIN AND IMPROVE THE HEALTH AND WELL-BEING OF CUSTOMERS.</li></li></ul><li>HEADQUARTER IN BASEL<br />
  7. 7. HUMAN RESOURCE <br />BUILDING OF NOVARTIS<br />IN BASEL.<br />
  8. 8. KEY PEOPLE<br />CHAIRMAN : DANIEL VASELLA<br />CEO: JOSEPH JIMENEZ<br />
  9. 9. <ul><li>REVENUE:US $44.27BILLION
  10. 10. NETINCOME:US$8.40BILLION
  11. 11. OPERATING INCOME:US $9.98
  12. 12. EMPLOYEES:99,830
  13. 13. SUBSIDIARIES:CIBAVISION,SANDOZ</li></li></ul><li>NOVARTIS WINS TWO<br /> SCRIP AWARDS FOR <br />BEST OVERALL PIPELINE<br />AND CORPORATE SOCIAL <br />RESPONSIBILITY.<br />
  14. 14.
  15. 15. SHARE ANALYSIS OF NOVARTIS<br />
  16. 16. GROWTH IN VARIOUS PRODUCT CATEGORIES…..<br />
  17. 17. EMERGING MARKETS<br />OF NOVARTIS<br /><ul><li>CHINA
  18. 18. RUSSIA
  19. 19. TURKEY
  20. 20. SOUTH KOREA
  21. 21. BRAZIL
  22. 22. INDIA</li></li></ul><li>
  23. 23. EMERGING MARKKETS IN PHARMACEUTICALS..<br />
  24. 24. SOME IMP. FACTS<br /><ul><li>WE OFFER A BROAD RANGE OF HEALTHCARE SOLUTIONS THAT MEETS</li></ul>THE EVOLVING AND UNMET NEEDS OF PATIENTS AND SOCITIES<br />WORLDWIDE.<br /><ul><li>OUR MEDICINES AND VACCINES PROTECTED 930 MILLION</li></ul>PEOPLE IN 2009.<br /><ul><li>STRONG FINANCIAL PERFORMANCE SHOWS OUR ABILITY TO</li></ul>TO FULFILL OUR PRIMARY MISSIONTO CARE AND CURE..<br /><ul><li>WHERE INTEGERITY AND HIGH ETHICAL STANDARDS REMAINS</li></ul>ESSENTIAL TO OUR LONG TERM SUCCESS. <br />
  25. 25. ABOUT COMPANY<br /><ul><li>A PHARMACEUTICAL COMPANY
  26. 26. FOUNDED IN 1996,
  27. 27. HD.QT’S-BASEL AND SWITZERLAND.
  28. 28. RANKING 3 IN SALES AMONG</li></ul> WORLDWIDE INDUSTRY.<br /><ul><li>IS 6TH LARGEST IN TERMS OF REVENUE..
  29. 29. IS MEMBER OF EUROPEAN FEDERATION OF</li></ul>PHARMACEUTICAL INDUSTRIES ANDASSOCIATION.<br />
  30. 30. NOVERTIS PRODUCTS<br />
  31. 31. USD FIXED INCOME SECURITIES<br />
  32. 32. FINANCIAL DEVELOPMENTS IN<br />2009<br />NET SALES:RISE 7%(+11% IN LOCAL CURRENCY TO USD 44.3BILLION.<br />PHARMACEUTICALS: RANKS AS ONE OF THE INDUSTRY FAST GROWING COMPANIES IN 2009 WITH NET SALES OF 8%(+12% IN LC) TO USD 28.5BILLION.<br />VACCINES AND DIAGNOSTICS:38%(39% IN LC) NET SALES INCCREASE TO USD 2.4 BILLION..<br />SANDOZ: NET SALES FALLS 1% TO USD 7.5 BILLION BUT RISE 5%LC AS NEGATIVE CURRENCY OVERSHADOWS OPERATIONAL GAINS FROM NEW LAUNCHES.<br />CONSUMER HEALTH:EXPAND MARKET SHARE IN ALL BUSINESS ECONOMIC ACTIVITIES WITH SALES OF USD 5.8 BILLION.<br />;<br />
  33. 33. SOME OTHER FINANCIAL<br />DEVELOPMENTS<br />OPERATING INCOME:ADVANCES 11% TO USD 10.0 BILLION ON THE SOLID BUSINESS EXPANSIONAND PRODUCTIVITY GAINS MORE DUE TO NEGATIVE IMPACT OF LOCAL CURRENCY.<br />NET INCOME:GROWS 4% TO USD 8.5 BILLION DUE TO RELATED FINANCIAL COST AND INCOME FROM ASSOCIATED COMPANIES.<br />BASIC EARNING PER SHARE:RISE FROM 3% TO 3.70,CORE EPS RISES FROM 8% TO USD 4.50.<br />DIVIDEND:INCREASES 3.7%<br />PRODUCTIVITY:EXCEEDING THE TARGET BY 0.7 BILLION.<br />
  34. 34. WHAT TYPE OF BUSINESS WE ARE IN??<br /><ul><li>PHARMACEUTICAL
  35. 35. VACCINES AND DIAGNOSTICS
  36. 36. SANDOZ(GENERICS)
  37. 37. OVER THE COUNTER
  38. 38. ANIMAL HEALTH
  39. 39. CIBA VISION</li></li></ul><li>Comtan- $420 M (2007)- Parkinson's disease<br />Diovan- $5.0 B sales[25] (2007)- Hypertension<br />Exjade- $357 M (2007) - Ironchelator<br />Femara- $937 M (2007)- Breast cancer<br />Gleevec- $3.1 B- for Chronic myeloid leukemia<br />Lescol- $665 M (2007)- hypercholesterolemia<br />Lotrel- $748 M (2007)- Hypertension<br />Lucentis- $393 M (2007)- Age-related macular degeneration<br />Ritalin- $375 M (2007) - AD/HD<br />Exelon- $632 M (2007)- Alzheimer's disease<br />Sandimmune and Neoral- $944 M (2007)- Organ transplantation<br />Sandostatin - $1.0 B (2007) - Acromegaly<br />Tegretol- $413 M (2007)- Epilepsy<br />Termalgin - (Paracetamol and compounds.) - Treatment of fever and light pain.<br />Tobramycin- $273 M (2007)- Cystic fibrosis<br />Trileptal- $692 M (2007)- Epilepsy<br />Voltaren- $747 M (2007)- anti-inflammatory<br />Zometa- $1.3 B (2007)- Cancer complications<br />Tofranil- - antidepressant<br />PHARMACEUTICALS<br />
  40. 40. HEALTHCARE OTC<br />Benefiber<br />Buckley's cold and cough formula<br />Bufferin<br />Comtrex cold and cough<br />Denavir/Vectavir<br />Desenex<br />Doan's pain relief<br />Ex-Lax<br />Excedrin<br />Fenistil<br />Gas-X<br />Habitrol<br />Keri skin care<br />Lamisil foot care<br />Lipactin Herpes symptomatic treatment<br />Maalox<br />Nicotinell<br />No-doz<br />
  41. 41. ANIMAL CARE<br /><ul><li>PETS CARE</li></ul>Interceptor (Milbemycin oxime), oral worm control product<br />Sentinel Flavor Tabs (Milbemycin oxime, Lufenuron), oral flea control product<br />Deramaxx (Deracoxib), oral treatment for pain and inflammation from osteoarthritis in dogs<br />Caps tar (Nitenpyram), oral tablet for flea control<br />Milbemax (Milbemycin oxime, Praziquantel), oral worm treatment<br />Program (Lufenuron), oral tablet for flea control<br /><ul><li>LIVESTOCK</li></ul>Acatalk Duostar (Fluazuron, Ivermectin), tick control for cattle<br />CLiK (Dicyclanil), blowfly control for sheep<br />Denagard (Tiamulin)<br />Fasinex (Triclabendazole)<br />ViraShield<br />
  42. 42. NET SALES BY REGION IN %<br />
  43. 43. CORE OPERATING INCOME <br />BY DIVISION IN %<br />
  44. 44. NET SALES BY DIVISION IN %<br />
  45. 45. COMPETITORS IN INDIA<br />NAME OF THE COUNTRY<br />DR.REDDY’S LAB<br />CIPLA<br />PIRAMAL HEALTHCARE<br />GLAXO INDIA LTD.<br />SUN PHARMACEUTICAL<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />1.5 <br />1.28<br />0.84<br />0.43<br />0.42<br />
  46. 46. COMPETITORS IN SWITZERLAND<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />47.35<br />4.26<br />NAME OF THE COUNTRY<br />HOFFMAN LA ROCHE<br />2.NYCOMED<br />
  47. 47. COMPETITORS IN GERMANY<br />NAME OF THE COUNTRY<br />BAYER<br />BOEHRINGER INGELHEIM<br />MERCK kGaA<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />22.3<br />16.9<br />5.17<br />
  48. 48. COMPETITORS IN JAPAN<br />NAME OF THE COUNTRY<br />TAKEDAPHARMACEUTICAL.<br />ASTELLAS PHARMA<br />DAIICHI SANKYO 9<br />EISAI<br />CHUGAI PHARMACEUTICAL .<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />15.6<br />10.7<br />9<br />5.5<br />2.0<br />
  49. 49. COMPETITORS IN USA<br />TOTAL REVENUE(IN USD BILLIONS )<br />61.90<br />30.76 <br /> 27.43 <br />21.84<br />18.81<br />NAME OF THE COMPANY<br />JOHNSON AND JOHNSON<br />ABOTT LABORATORIES<br />MERC K AND CO.<br />ELI LILLY<br />BRISTOL MAYER SQUIBB<br />
  50. 50. COMPETITORS IN UK<br />NAMEOF THE COMPANY<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />45.83<br /> 32.81<br />GlaxoSmithKline<br />AstraZeneca<br />
  51. 51.
  52. 52.
  53. 53.
  54. 54. 2009 net sales - USD 7.5 billion<br />                                                                                                                                                     <br />DIOVAN<br />
  55. 55. CHEMICAL DATA<br /><ul><li>FORMULA:C24H29N5O3
  56. 56. MOL.MAS:435.519G/MOL
  57. 57. SMILES:eMolecules AND Pubchem</li></li></ul><li>Pharmacokinetic data<br /><ul><li>Bioavailability:25%
  58. 58. Protein binding:95%
  59. 59. Half life :6hours
  60. 60. Excretion:renal 30%,biliary70%</li></li></ul><li>DIOVAN IS INDICATED<br />FOR THE TREATMENT <br />OF<br /><ul><li> HIGH BLOOD PRESSURE,
  61. 61. HEART FAILURE AND
  62. 62. MYOCARDIAL INFARCTION.</li></li></ul><li>FOR THE DIABETES PATIENTS<br />In patients with impaired glucose tolerance, valsartan may decrease the incidence of developing type 2 diabetes mellitus. However, the absolute risk reduction is small (<1%/year) and diet + exercise or other drugs, maybe more protective. In the same study, no reduction in the rate of cardiovascular events (including death) was shown. In other words, taking Valsartan didn't make the patients live longer.<br />
  63. 63.
  64. 64.
  65. 65. BRANDS<br /><ul><li>IN US , VALSARTAN IS MARKETED UNDER TRADE MARK DIOVAN.
  66. 66. IN PAKISTAN ,IT IS MARKETED UNDER TRADE MARK ANGIOTAN.
  67. 67. IN INDIA,IT IS MARKETED BY CIPLA UNDER TRADE MARK VALTAN AND BY TORRENT PHARMACEUTICALS UNDER NAME VALZAAR.</li></li></ul><li>
  68. 68.
  69. 69.
  70. 70. SIDE EFFECTS OF DIOVAN<br />LEADS TO HEADACHE AND DIZZINESS.<br />SENSTIVITY TO SUNLIGHT AND BRIGHT ARTIFICIAL LIGHT.<br />THERE IS A CASE OF A STILLBIRTH IN WHICH VALSARTAN IS<br />IMPLICATED.<br />
  71. 71. THANKS<br />

×